LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular is supported by durable pricing power, with management expecting a similar approach in 2027 after years of high-single-digit pricing tailwinds, aided by niche products that represent only 5-10% of a procedure’s cost and by expanding use of price floors and direct sales. Its latest 1Q26 results reinforced that thesis, as revenue reached $66.6 million with 10% organic growth, gross margin expanded 350 bps to 72.7%, adjusted EBITDA rose to $20.3 million, and adjusted EPS jumped 42% to $0.68, while FY/26 EPS guidance was raised to $2.93-$3.08. The company also has strong optionality from international expansion and M&A, including $367.2 million of cash and marketable securities, $15.1 million of operating cash flow in 1Q26, and growing Artegraft/RestoreFlow opportunities across EMEA, APAC, and the cardiac space.

LeMaitre Vascular is exposed to meaningful fundamental headwinds despite recent 10% organic revenue growth and $66.6 million in quarterly revenue, because the top-line beat is modest and the business remains vulnerable to geographic mix pressure in the Americas, which still generated $41.6 million. Its outlook is further constrained by international regulatory risk, since sales outside the U.S. have represented 40% of revenue and the company must secure and maintain MDR CE marks through December 2027 and December 2028 for certain devices, creating execution uncertainty. Growth also depends on a limited pool of acquisition targets, while manufacturing and tissue-processing disruptions could impair operations, quality standards, and accreditation, leaving the stock exposed to uneven expansion and margin risk.